JP6349304B2 - 上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 - Google Patents

上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 Download PDF

Info

Publication number
JP6349304B2
JP6349304B2 JP2015509432A JP2015509432A JP6349304B2 JP 6349304 B2 JP6349304 B2 JP 6349304B2 JP 2015509432 A JP2015509432 A JP 2015509432A JP 2015509432 A JP2015509432 A JP 2015509432A JP 6349304 B2 JP6349304 B2 JP 6349304B2
Authority
JP
Japan
Prior art keywords
composition
poly
microparticles
starch
microparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015509432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515968A5 (cg-RX-API-DMAC10.html
JP2015515968A (ja
Inventor
アルバート マルコム，ブルース
アルバート マルコム，ブルース
パウルス マリア ストミュラー，ロジャー
パウルス マリア ストミュラー，ロジャー
エルビア コレット バート，リーベン
エルビア コレット バート，リーベン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48430695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6349304(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2015515968A publication Critical patent/JP2015515968A/ja
Publication of JP2015515968A5 publication Critical patent/JP2015515968A5/ja
Application granted granted Critical
Publication of JP6349304B2 publication Critical patent/JP6349304B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015509432A 2012-05-03 2013-05-02 上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 Expired - Fee Related JP6349304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12166595.4 2012-05-03
EP12166595 2012-05-03
PCT/EP2013/059079 WO2013164380A1 (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Publications (3)

Publication Number Publication Date
JP2015515968A JP2015515968A (ja) 2015-06-04
JP2015515968A5 JP2015515968A5 (cg-RX-API-DMAC10.html) 2016-06-30
JP6349304B2 true JP6349304B2 (ja) 2018-06-27

Family

ID=48430695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509432A Expired - Fee Related JP6349304B2 (ja) 2012-05-03 2013-05-02 上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤

Country Status (17)

Country Link
US (3) US9682096B2 (cg-RX-API-DMAC10.html)
EP (1) EP2846767B1 (cg-RX-API-DMAC10.html)
JP (1) JP6349304B2 (cg-RX-API-DMAC10.html)
KR (1) KR102240042B1 (cg-RX-API-DMAC10.html)
CN (1) CN104394846B (cg-RX-API-DMAC10.html)
AU (1) AU2013255885C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014026957A8 (cg-RX-API-DMAC10.html)
CA (1) CA2866230C (cg-RX-API-DMAC10.html)
CL (1) CL2014002929A1 (cg-RX-API-DMAC10.html)
CO (1) CO7101247A2 (cg-RX-API-DMAC10.html)
ES (1) ES2911116T3 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02359A (cg-RX-API-DMAC10.html)
MX (1) MX2014013256A (cg-RX-API-DMAC10.html)
NZ (1) NZ630040A (cg-RX-API-DMAC10.html)
RU (1) RU2650636C2 (cg-RX-API-DMAC10.html)
SG (2) SG11201406208QA (cg-RX-API-DMAC10.html)
WO (1) WO2013164380A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535094A (ja) * 2013-11-06 2016-11-10 ヤンセン・サイエンシズ・アイルランド・ユーシー 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406208QA (en) 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
HK1251926A1 (zh) * 2015-05-11 2019-05-03 Janssen Sciences Ireland Uc 用於预防和/或治疗上呼吸道感染的聚肌苷酸-聚胞苷酸(聚(i:c))豌豆淀粉制剂
PT3319587T (pt) 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
US20200060972A1 (en) 2016-11-16 2020-02-27 Janssen Sciences Ireland Unlimited Company Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections
JP2020520368A (ja) 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP7296644B2 (ja) * 2018-06-29 2023-06-23 信福（北京）医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
WO2026112449A1 (en) 2024-11-21 2026-05-28 Rigimmune Inc. Formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
KR100259989B1 (ko) 1991-10-01 2000-08-01 모리다 가쓰라 서방성 마이크로캡슐 제제 및 그의 제조법
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
JP2004510723A (ja) * 2000-10-06 2004-04-08 ヤゴテック　アーゲー 低下した分子量のアミロペクチンをベースとする精製された澱粉を含む制御放出投与のための生物分解性微粒子
WO2004041183A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
CA2548992A1 (en) 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
CN101229378A (zh) 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
KR101203401B1 (ko) 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
ES2391671T3 (es) 2006-07-22 2012-11-28 Oxagen Limited Compuestos con actividad antagonista de CRTH2
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
US9498431B2 (en) * 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
CN101491503A (zh) 2008-12-17 2009-07-29 天津瑞普生物技术股份有限公司 一种用于宠物的聚肌胞滴丸及其制备方法
PT3098239T (pt) 2008-12-22 2020-01-15 Targimmune Therapeutics Ag Vetor de rna de cadeia dupla dirigido ao egfr para o tratamento sistémico de cancro
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法
AU2010232180B2 (en) 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
SG11201406208QA (en) 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
KR20160072140A (ko) 2013-11-06 2016-06-22 얀센 사이언시즈 아일랜드 유씨 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535094A (ja) * 2013-11-06 2016-11-10 ヤンセン・サイエンシズ・アイルランド・ユーシー 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤

Also Published As

Publication number Publication date
BR112014026957A8 (pt) 2018-01-16
CN104394846B (zh) 2018-10-19
CA2866230A1 (en) 2013-11-07
EP2846767B1 (en) 2022-01-26
KR102240042B1 (ko) 2021-04-14
CL2014002929A1 (es) 2015-01-16
NZ630040A (en) 2016-10-28
SG10201607288VA (en) 2016-10-28
CA2866230C (en) 2020-08-18
SG11201406208QA (en) 2014-11-27
HK1203390A1 (en) 2015-10-30
US20160296551A1 (en) 2016-10-13
KR20150008855A (ko) 2015-01-23
ES2911116T3 (es) 2022-05-17
CO7101247A2 (es) 2014-10-31
US10485816B2 (en) 2019-11-26
BR112014026957A2 (pt) 2017-06-27
JP2015515968A (ja) 2015-06-04
EP2846767A1 (en) 2015-03-18
IN2014MN02359A (cg-RX-API-DMAC10.html) 2015-08-14
US9682096B2 (en) 2017-06-20
RU2650636C2 (ru) 2018-04-16
US20180325939A1 (en) 2018-11-15
US9987300B2 (en) 2018-06-05
MX2014013256A (es) 2015-01-16
CN104394846A (zh) 2015-03-04
AU2013255885A1 (en) 2014-09-25
AU2013255885B2 (en) 2017-10-05
US20150140042A1 (en) 2015-05-21
WO2013164380A1 (en) 2013-11-07
RU2014148544A (ru) 2016-06-27
AU2013255885C1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US10485816B2 (en) Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
JP6629216B2 (ja) 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤
JP2018515530A (ja) 上気道感染症の予防および／または治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））のエンドウマメデンプン製剤
US20200060972A1 (en) Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections
CN119118800A (zh) 一种超声辅助自组装白藜芦醇纳米晶及其制备方法和应用
HK1203390B (en) Polyinosinic-polycytidylic acid (poly(i:c)) formulations for the treatment of upper respiratory tract infections
Jha et al. Polymeric nanomaterials for infectious diseases
HK1228749A1 (en) Polyinosinic-polycytidylic acid (poly (i:c) formulations for the treatment of upper respiratory tract infections

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180604

R150 Certificate of patent or registration of utility model

Ref document number: 6349304

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees